Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Cempra Releases Promising Phase II Clinical Trial Results For Anti-NASH Drug

XTALKS VITALS NEWS

Between 10 and 20 percent of patients with nonalcoholic fatty liver disease (NAFLD) suffer from NASH, which is a progressive form of the disease characterized by excessive fat accumulation, inflammation and fibrosis.

Tweetables from this article:

Tweet: #NASH affects up to five percent of the US population and can progress into liver #cirrhosis and #cancer http://ctt.ec/Gc0U5+ NASH affects up to five percent of the US population and can progress into liver cirrhosis and cancer.

Share this!

October 5, 2016 | by Sarah Hand, M.Sc.

Antibiotics developer Cempra Inc. has released positive interim results from a Phase II clinical trial for their drug, solithromycin, in the treatment of non-alcoholic steatohepatitis (NASH). Between 10 and 20 percent of patients with nonalcoholic fatty liver disease (NAFLD) suffer from NASH, which is a progressive form of the disease characterized by excessive fat accumulation, inflammation and fibrosis.

With no known cure, NASH affects up to five percent of the US population and can progress into liver cirrhosis and potentially cancer in some patients. The growing market has attracted a handful of pharmaceutical companies looking to develop a treatment for NASH.

In a small Phase II clinical trial of six patients with NASH, solithromycin was able to reduce the NAFLD activity score (NAS) – a tool used to measure changes in the disease – by an average of 1.3. According to Cempra, the drug was well-tolerated in patients and the company plans to continue the clinical trial.

“We have been focusing on new treatments for NASH for the past 15 years and the early results we have seen with solithromycin are very promising for a patient population that urgently needs a new treatment option,” said Dr. Pierre Gholam, from Case Western Reserve University School of Medicine and principal investigator of the study. “While this is a small number of patients and further work is required to confirm these data on a wider scale, the observation that solithromycin was able to lower NAS by an average of 1.3 points in just 13 weeks with a good safety profile does allow a good measure of optimism.”



Cempra’s solithromycin is an antibacterial drug effective against most macrolide-resistant community acquired bacterial pneumonia (CABP) infections. The total course of therapy in this clinical trial was completed after just over 3 months.

“We are very excited to see that these early clinical results with solithromycin in NASH patients are confirming the results we saw in our pre-clinical studies,” said Dr. Prabhavathi Fernandes, president and chief executive officer of Cempra, “and we look forward to continuing to investigate this important unmet medical need.”

Cempra expects to complete enrollment in this study during the first quarter of 2017. Allergan is another company hoping to break into the NASH market after acquiring Akarna Therapeutics and Tobira Therapeutics last month.


Keywords: NASH, Liver, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.